Patient Treatment Preferences in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) (P7-1.009)

June 9, 2026Neurology

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research aims to understand how patients with MOGAD prioritize treatment benefits against risks and disease impacts.
Qualitative assessment of patient preferences regarding treatment options.
Evaluation of key factors influencing treatment decisions.
Analysis of balance between perceived risks and benefits in treatment.
Patients expressed a strong preference for treatments that increase quality of life despite potential risks.
Risk tolerance varied significantly among individuals, affecting their treatment choices.
Many patients prioritize long-term outcomes over short-term treatment side effects.

This research explores patient preferences concerning treatment risks and benefits in MOGAD, highlighting their choices.

To understand the preferences of patients with MOGAD when balancing disease impacts, treatment risks and treatment benefits.

No takes yet. Share an insight, caveat, or question.

Abboud et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share